These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 27061369)

  • 1. Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013).
    Castanheira M; Messer SA; Rhomberg PR; Pfaller MA
    Diagn Microbiol Infect Dis; 2016 Jun; 85(2):200-4. PubMed ID: 27061369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
    Jensen RH
    Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
    Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
    Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).
    Pfaller MA; Messer SA; Jones RN; Castanheira M
    J Antibiot (Tokyo); 2015 Sep; 68(9):556-61. PubMed ID: 25899126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
    Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
    Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
    Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Int J Antimicrob Agents; 2017 Sep; 50(3):352-358. PubMed ID: 28689871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
    Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey.
    Rambach G; Oberhauser H; Speth C; Lass-Flörl C
    Med Mycol; 2011 Nov; 49(8):856-63. PubMed ID: 21619497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands.
    van Ingen J; van der Lee HA; Rijs TA; Zoll J; Leenstra T; Melchers WJ; Verweij PE
    J Antimicrob Chemother; 2015 Jan; 70(1):178-81. PubMed ID: 25301884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study.
    González GM; Treviño-Rangel Rde J; Palma-Nicolás JP; Martínez C; González JG; Ayala J; Caballero A; Morfín-Otero R; Rodríguez-Noriega E; Velarde F; Ascencio EP; Tinoco JC; Vázquez JA; Cano MA; León-Sicairos N; González R; Rincón J; Elías MA; Bonifaz A
    J Antimicrob Chemother; 2013 Dec; 68(12):2847-51. PubMed ID: 23869052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.
    Pfaller MA; Castanheira M; Messer SA; Jones RN
    Mycoses; 2015 Apr; 58(4):209-14. PubMed ID: 25727853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.
    Pfaller MA; Woosley LN; Messer SA; Jones RN; Castanheira M
    Mycopathologia; 2012 Oct; 174(4):259-71. PubMed ID: 22580756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.